

FOR IMMEDIATE RELEASE
Contact: Mark N. Schwartz, CEO
(651) 687-9999

Hypertension Diagnostics Announces Fiscal Year 2009 Results

Strong fourth quarter revenue and encouraging outlook for first quarter

ST. PAUL, MN – September 18, 2009 – Hypertension Diagnostics, Inc. (OTC: HDII.OB), today announced audited financial results for the fiscal year ended June 30, 2009.

Revenue for fiscal year 2009 totaled \$503,175 compared to \$554,454 in the prior year ended June 30, 2008, which represents a 9.2% decrease. The Company incurred a net loss of \$248,440 for fiscal year 2009 or \$(.01) per share, compared with a net loss of \$703,837 for fiscal year 2008, or \$(.02) per share. Included in the net loss for fiscal year 2009 are total non-cash benefits (mainly deferred stock compensation, depreciation, stock options) of \$125,102. Included in the net loss for fiscal year 2008 are total non-cash charges of \$187,078. The benefit for the twelve month period ended June 30, 2009 is a result of the decrease in the Company's stock price, which caused the non-cash deferred compensation expense to become a non-cash benefit. The Company reported a cash balance on June 30, 2009 of \$697,918.

Fourth quarter revenue of \$164,691, for fiscal year 2009 compared to \$159,176 for fiscal year 2008, represented a 3.5% increase. Revenue for the fourth quarter of fiscal year 2009 increased by 154.3% compared with \$64,765 for the third quarter of fiscal year 2009.

"We are pleased with the rebound in our fourth quarter sales, most of which occurred in the month of June and which appears to be gaining momentum based on preliminary results for our first quarter of 2010," said Mark Schwartz, Chairman and CEO. "Our fourth quarter sales results provide some encouragement that our market is recovering. We continue to add new distributors in the U.S. and in international markets."

As previously reported the Company has been selected to have its research product used in 16 international sites for a study funded by the National Institutes of Health (NIH) to determine whether the measurement of arterial elasticity can assist in the prevention of cardiovascular disease in HIV patients. Most of the revenue from this sale will impact the Company's first and second quarter fiscal year 2010 results. "Even without the revenue from the NIH funded trial, the preliminary sales results for the first quarter of 2010 are encouraging," concluded Mr. Schwartz.

Forward-looking statements in this press release are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company wishes to caution readers not to place undue reliance on any forward-looking statements and to recognize that the statements are not a prediction of actual future results. Actual results could differ materially from those presented and anticipated in the forward-looking statements due to the risks and uncertainties set forth in the Company's 2009 Annual Report on Form 10-K, and subsequent Quarterly Reports on Form 10-Q, all of which were filed with the U.S. Securities and Exchange Commission, as well as others not now anticipated.

Hypertension Diagnostics, Inc.
Summary Financial Data

Statements of Operations

	Three Months Ended		Twelve Months Ended	
	June 30		June 30	
	2009	2008	2009	2008
Revenue:				
Equipment sales	\$ 125,850	\$ 112,479	\$ 332,687	\$ 342,305
Equipment rental	19,420	36,972	86,863	150,786
Service/contract income	19,421	9,725	83,625	61,363
	<u>164,691</u>	<u>159,176</u>	<u>503,175</u>	<u>554,454</u>
Cost of Sales	3,284	10,116	10,991	44,329
Gross Profit	<u>161,407</u>	<u>149,060</u>	<u>492,184</u>	<u>510,125</u>
Total Expenses	<u>322,649</u>	<u>220,480</u>	<u>753,768</u>	<u>1,259,874</u>
Operating Loss	<u>(161,242)</u>	<u>(71,420)</u>	<u>(261,584)</u>	<u>(749,749)</u>
Other Income:				
Interest income	<u>1,351</u>	<u>7,168</u>	<u>13,144</u>	<u>45,912</u>
Total Other Income	<u>1,351</u>	<u>7,168</u>	<u>13,144</u>	<u>45,912</u>
Net (Loss) Income	<u>\$ (159,891)</u>	<u>\$ (64,252)</u>	<u>\$ (248,440)</u>	<u>\$ (703,837)</u>
Basic and Diluted Net Loss per Share	\$ (.00)	\$ (.00)	\$ (.01)	\$ (.02)
Weighted Average Shares Outstanding	40,939,193	39,771,500	40,722,471	39,690,323

Balance Sheet Data

	<u>June 30, 2009</u>	<u>June 30, 2008</u>
Cash and cash equivalents	\$ 697,918	\$ 1,081,868
Total current assets	1,022,528	1,408,379
Total assets	1,032,787	1,427,786
Total current liabilities	340,384	585,280
Accumulated deficit	(27,434,607)	(27,186,167)
Total shareholders' equity	660,041	816,981
	# # #	

CVProfilor is a registered trademark of Hypertension Diagnostics, Inc.

Hypertension Diagnostics, HDI/PulseWave, PulseWave and CVProfile are trademarks of Hypertension Diagnostics, Inc. All rights reserved.

Website: www.hdii.com